Bio-Rad’s four new antibodies will develop highly selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars.
Bio-Rad Laboratories, a life science technology company, announced four new anti-pertuzumab antibodies on Jan. 31, 2022. These ready-made antibodies are designed to inhibit the binding of the drug to its goal, human epidermal development tissue 2 (HER2), which enables researchers to develop selective assays for bioanalysis and monitoring of pertuzumab and its biosimilars.
The HER2 protein is over-expressed in HER2-positive cancers, stopping cell development and proliferation. Pertuzumab and its biosimilars are designed to bind to this protein as a form of treatment for these cancers.
The new assays include monovalent form antibodies, which are appropriate for pharmacokinetic bridging enzyme-linked immunoassays. Additionally, there are human immunoglobulin G1 antibodies with various ranges of affinity, which can be used as a surrogate for constructive management.
“We’re constantly introducing new ranges of recombinant, monoclonal anti-idiotypic antibodies to assist researchers in creating strong strategies that ship reproducible and translatable outcomes,” stated Amanda Turner, Bio-Rad product supervisor, Life Science Group, in the press release.
This product is authorized for in-vitro analysis functions, as well as for industrial providers offering in-vitro testing to assist preclinical and scientific drug growth.
Source: Bio-Rad
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.